PT1895010E - Vectores com base no vírus da anemia infecciosa equina (eiav) - Google Patents
Vectores com base no vírus da anemia infecciosa equina (eiav) Download PDFInfo
- Publication number
- PT1895010E PT1895010E PT07015653T PT07015653T PT1895010E PT 1895010 E PT1895010 E PT 1895010E PT 07015653 T PT07015653 T PT 07015653T PT 07015653 T PT07015653 T PT 07015653T PT 1895010 E PT1895010 E PT 1895010E
- Authority
- PT
- Portugal
- Prior art keywords
- eiav
- based vectors
- equine infectious
- anaemia virus
- infectious anaemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15061—Methods of inactivation or attenuation
- C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9727135.7A GB9727135D0 (en) | 1997-12-22 | 1997-12-22 | Non-primate lentiviral vectors |
| GBGB9811037.2A GB9811037D0 (en) | 1998-05-22 | 1998-05-22 | Proretoviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1895010E true PT1895010E (pt) | 2012-01-25 |
Family
ID=26312829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07015653T PT1895010E (pt) | 1997-12-22 | 1998-12-22 | Vectores com base no vírus da anemia infecciosa equina (eiav) |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6312683B1 (pt) |
| EP (2) | EP1042493A1 (pt) |
| JP (1) | JP4578678B2 (pt) |
| CN (1) | CN1322137C (pt) |
| AT (1) | ATE528405T1 (pt) |
| AU (1) | AU760287B2 (pt) |
| CA (1) | CA2315269A1 (pt) |
| CY (1) | CY1112196T1 (pt) |
| DK (1) | DK1895010T3 (pt) |
| ES (1) | ES2373406T3 (pt) |
| PT (1) | PT1895010E (pt) |
| WO (1) | WO1999032646A1 (pt) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070213290A1 (en) * | 1996-10-17 | 2007-09-13 | Kingsman Alan J | Neurite regeneration |
| US20040266715A1 (en) * | 1999-03-31 | 2004-12-30 | Wong Liang Fong | Neurite regeneration |
| DK1895010T3 (da) * | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6849454B2 (en) | 2000-03-07 | 2005-02-01 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
| WO2001066150A2 (en) * | 2000-03-07 | 2001-09-13 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles |
| AU2001244354A1 (en) * | 2000-03-30 | 2001-10-15 | Oxford Biomedica (Uk) Limited | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disorders |
| GB0009760D0 (en) * | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US20040018211A1 (en) * | 2002-06-26 | 2004-01-29 | Ronald Montelaro | EIA vaccine and diagnostic |
| JP2004522697A (ja) * | 2000-09-09 | 2004-07-29 | アクゾ・ノベル・エヌ・ベー | Ｅｉａｖキメラワクチンおよび診断 |
| US6585978B1 (en) * | 2000-09-09 | 2003-07-01 | Akzo Nobel | EIA vaccine and diagnostic |
| US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
| EP1317273B1 (en) * | 2000-09-14 | 2006-05-03 | Ares Trading S.A. | Use of il-6r/il-6 chimera in huntington's disease |
| GB0024550D0 (pt) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| US20030175972A1 (en) * | 2000-10-20 | 2003-09-18 | Daley George Q. | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| AU2002327412A1 (en) * | 2001-08-02 | 2003-02-17 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| WO2003029274A2 (en) * | 2001-09-28 | 2003-04-10 | University Of North Carolina At Chapel Hill | Paramyxoviruses as gene transfer vectors to lung cells |
| NZ532060A (en) | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
| US20030121062A1 (en) * | 2001-12-21 | 2003-06-26 | Oxford Biomedica (Uk) Limited | Transgenic organism |
| AU2002353231B2 (en) * | 2001-12-21 | 2008-10-16 | Oxford Biomedica (Uk) Limited | Method for producing a transgenic organism using a lentiviral expression vector such as EIAV |
| ES2634424T3 (es) | 2002-02-01 | 2017-09-27 | Oxford Biomedica (Uk) Limited | Vector multicistrónico lentivírico |
| US9738907B2 (en) | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
| US7662625B2 (en) * | 2002-07-02 | 2010-02-16 | Cancer Research Technology Limited | Methods for detecting the differentiation status of cells using 5T4 antigen expression |
| GB0215287D0 (en) * | 2002-07-02 | 2002-08-14 | Oxford Biomedica Ltd | 5T4 antigen expression |
| AU2003260769A1 (en) * | 2002-09-03 | 2004-03-29 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| US20050251872A1 (en) * | 2002-09-06 | 2005-11-10 | Bear James E | Lentiviral vectors, related reagents, and methods of use thereof |
| DK1563069T3 (da) * | 2002-11-22 | 2012-07-23 | Inst Clayton De La Rech | Sammensætninger og systemer til genregulering |
| EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| CN100562570C (zh) | 2003-06-18 | 2009-11-25 | 吉恩勒克斯公司 | 修饰的重组痘苗病毒及其它微生物,及其应用 |
| ES2417019T3 (es) | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa |
| US20050202484A1 (en) | 2004-02-19 | 2005-09-15 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US20060233757A1 (en) * | 2004-08-27 | 2006-10-19 | Wendy Maury | Vectors with viral insulators |
| RS51324B (sr) | 2005-04-25 | 2010-12-31 | Merial Ltd. | Vakcine protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7598364B2 (en) | 2005-11-14 | 2009-10-06 | Merial Limited | Plasmid encoding canine BMP-7 |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| CN101705246B (zh) * | 2007-04-29 | 2012-06-27 | 中国农业科学院哈尔滨兽医研究所 | 慢病毒基因转移载体、其制备方法和应用 |
| CA2705862C (en) | 2007-11-16 | 2018-03-27 | San Diego State University Research Foundation | Compositions and method for manipulating pim-1 activity in circulatory system cells |
| CN102428099B (zh) | 2009-04-03 | 2016-03-16 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
| JP5913316B2 (ja) | 2010-08-31 | 2016-04-27 | メリアル リミテッド | ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| AP2013007180A0 (en) | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
| CA2837375C (en) | 2011-06-01 | 2019-07-16 | Merial Limited | Needle-free administration of prrsv vaccines |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| WO2014093965A1 (en) * | 2012-12-14 | 2014-06-19 | Case Western Reserve University | Genomic rna packaging enhancer element |
| US9556419B2 (en) | 2013-03-12 | 2017-01-31 | Merial Inc. | Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof |
| GB201318804D0 (en) * | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| WO2016073410A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| BR112017027895A2 (pt) | 2015-06-23 | 2018-11-06 | Merial Inc | vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes |
| WO2017091786A1 (en) | 2015-11-23 | 2017-06-01 | Novartis Ag | Optimized lentiviral transfer vectors and uses thereof |
| WO2018167486A1 (en) | 2017-03-15 | 2018-09-20 | Oxford Biomedica (Uk) Limited | Method |
| EP3696272A1 (en) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviral vector |
| SG11202011015QA (en) | 2018-05-15 | 2020-12-30 | Flagship Pioneering Innovations V Inc | Fusosome compositions and uses thereof |
| KR20210043574A (ko) | 2018-07-09 | 2021-04-21 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 푸소좀 조성물 및 이의 용도 |
| AU2019380517A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| EP3880179A2 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| US20220333132A1 (en) | 2019-09-03 | 2022-10-20 | Sana Blotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| EP4058067A1 (en) | 2019-11-12 | 2022-09-21 | Oxford BioMedica (UK) Limited | Production system |
| KR20220119439A (ko) | 2019-12-20 | 2022-08-29 | 인스틸 바이오 유케이 리미티드 | 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도 |
| KR20220139911A (ko) | 2020-02-13 | 2022-10-17 | 옥스포드 바이오메디카(유케이) 리미티드 | 렌티바이러스 벡터의 생산 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| EP4118217A1 (en) | 2020-03-13 | 2023-01-18 | Oxford BioMedica (UK) Limited | Lentiviral vectors |
| WO2021202604A1 (en) | 2020-03-31 | 2021-10-07 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
| EP4143326A1 (en) | 2020-04-27 | 2023-03-08 | University of Iowa Research Foundation | Compositions and methods for the treatment of cystic fibrosis |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| WO2022130015A2 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| WO2022130017A2 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| TW202242121A (zh) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | 靶向cd8之病毒載體之用途 |
| CN117980495A (zh) * | 2021-03-24 | 2024-05-03 | 国家抗灾力公司 | 用于无细胞多肽合成的***和方法 |
| IL308836A (en) | 2021-05-28 | 2024-01-01 | Sana Biotechnology Inc | Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| JPWO2023038055A1 (pt) * | 2021-09-08 | 2023-03-16 | ||
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| WO2023077107A1 (en) | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
| TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024103025A1 (en) * | 2022-11-11 | 2024-05-16 | Rnaissance Ag Llc | Fermentation based method for double stranded rna production |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| JP3247972B2 (ja) * | 1990-05-28 | 2002-01-21 | 財団法人阪大微生物病研究会 | レトロウイルス遺伝子の多量発現能と翻訳後のプロセッシング能とを兼備するプラスミドの作製法、及びこれより得られるプラスミドとその発現産物 |
| CA2084659A1 (en) | 1990-06-20 | 1991-12-21 | Joseph G. Sodroski | Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof |
| US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| WO1992021750A1 (en) | 1991-05-29 | 1992-12-10 | THE UNITED STATES OF AMERICA, represented by THE SCRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Eukaryotic expression vectors with regulation of rna processing |
| JPH06261764A (ja) | 1993-02-17 | 1994-09-20 | Wisconsin Alumni Res Found | 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法 |
| JP4303315B2 (ja) * | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| EP0759471A4 (en) | 1994-05-10 | 1997-10-15 | Hisamitsu Pharmaceutical Co | RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF |
| EE03492B1 (et) * | 1994-09-02 | 2001-08-15 | GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH | Mitte-autoinaktiveeruvad ekspressiooni suunavad retroviiruslikud vektorid |
| US6300118B1 (en) * | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6033672A (en) * | 1996-03-15 | 2000-03-07 | University Of Southern California | Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens |
| DE69703974T2 (de) * | 1996-10-17 | 2001-07-19 | Oxford Biomedica Ltd | Retrovirale vektoren |
| JP2001513643A (ja) * | 1997-03-06 | 2001-09-04 | ウーベルラ、クラウス | レンチウイルスをベースとするベクター及びベクター系 |
| US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| JP4390860B2 (ja) * | 1997-05-13 | 2009-12-24 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | レンチウイルスをベースにした遺伝子転移ベクター |
| GB9720465D0 (en) * | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| EP1017797B1 (en) * | 1997-09-24 | 2005-06-22 | The Regents Of The University Of California | Non-primate lentiviral vectors and packaging systems |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DK1895010T3 (da) * | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
-
1998
- 1998-12-22 DK DK07015653.4T patent/DK1895010T3/da active
- 1998-12-22 ES ES07015653T patent/ES2373406T3/es not_active Expired - Lifetime
- 1998-12-22 WO PCT/GB1998/003876 patent/WO1999032646A1/en not_active Application Discontinuation
- 1998-12-22 EP EP98962602A patent/EP1042493A1/en not_active Withdrawn
- 1998-12-22 CA CA002315269A patent/CA2315269A1/en not_active Abandoned
- 1998-12-22 EP EP07015653A patent/EP1895010B1/en not_active Expired - Lifetime
- 1998-12-22 AU AU17732/99A patent/AU760287B2/en not_active Expired
- 1998-12-22 JP JP2000525564A patent/JP4578678B2/ja not_active Expired - Lifetime
- 1998-12-22 PT PT07015653T patent/PT1895010E/pt unknown
- 1998-12-22 CN CNB988137666A patent/CN1322137C/zh not_active Expired - Lifetime
- 1998-12-22 AT AT07015653T patent/ATE528405T1/de active
-
1999
- 1999-01-27 US US09/238,356 patent/US6312683B1/en not_active Expired - Lifetime
-
2001
- 2001-05-29 US US09/867,947 patent/US20030147907A1/en not_active Abandoned
-
2005
- 2005-06-15 US US11/154,421 patent/US20060024274A1/en not_active Abandoned
-
2011
- 2011-12-12 CY CY20111101230T patent/CY1112196T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112196T1 (el) | 2015-12-09 |
| US20030147907A1 (en) | 2003-08-07 |
| AU1773299A (en) | 1999-07-12 |
| ES2373406T3 (es) | 2012-02-03 |
| EP1042493A1 (en) | 2000-10-11 |
| EP1895010A2 (en) | 2008-03-05 |
| ATE528405T1 (de) | 2011-10-15 |
| JP4578678B2 (ja) | 2010-11-10 |
| US6312683B1 (en) | 2001-11-06 |
| EP1895010B1 (en) | 2011-10-12 |
| AU760287B2 (en) | 2003-05-08 |
| CN1322137C (zh) | 2007-06-20 |
| EP1895010A3 (en) | 2008-04-16 |
| US20060024274A1 (en) | 2006-02-02 |
| CA2315269A1 (en) | 1999-07-01 |
| CN1285000A (zh) | 2001-02-21 |
| WO1999032646A1 (en) | 1999-07-01 |
| DK1895010T3 (da) | 2011-11-21 |
| JP2002516065A (ja) | 2002-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1895010A3 (en) | Vectors based on equine infectious anemia virus (vaie) | |
| GB9803351D0 (en) | Anti-viral vectors | |
| CY1112985T1 (el) | Χρηση αλληλουχιων dνα τριπλου ελικα για τη μεταφορα νουκλεοτιδικων αλληλουχιων | |
| HUP0000442A2 (hu) | Lentivirális vektorok | |
| EP1394259A3 (en) | Recombinant infectious non-segmented negative strand RNA virus | |
| GB9510272D0 (en) | Retroviral vectors | |
| HK1105662A1 (en) | Sequences from natural or synthetic retroelements having the function of allowing the insertion of nucleotide sequences in a eukaryotic cell | |
| EP0783321A4 (en) | VIRAL NUCLEOTIDE SEQUENCE VR-2332 AND METHOD OF USE | |
| SI0935660T1 (sl) | Infekcijski kloni RNA virusov ter cepiva in diagnostični testi, izvedeni iz le-teh | |
| HUT69609A (en) | Hcv genomic sequences for diagnostics and therapeutics | |
| HK1010896A1 (en) | Primers for the detection of hiv-1 | |
| DK0461045T3 (pt) | ||
| EP0769553A4 (en) | DNA FRAGMENT, RECOMBINANT VECTOR THAT CONTAINS IT AND METHOD FOR EXPRESSING FOREIGN GENES WITH ITS USE | |
| PT630409E (pt) | Vectores nao oncovirais deficientes no empacotamento baseados no mpmv | |
| NZ508439A (en) | Novel endometriosis-associated gene | |
| DE69034052T2 (de) | Rekombinante vectoren , die für selbstzusammengesetzte, defekte, sich nichtselbstvermehrende viruspartikel kodieren | |
| DK631387A (da) | Virusvektor | |
| HK1084148A1 (en) | Mn gene and protein | |
| CA2191624A1 (en) | Dna fragment, recombinant vector containing the same and method for expressing foreign genes using the same | |
| EP0476670A3 (en) | Cloned n-carbamoylsarcosine-amidohydrolase | |
| EP0143615A3 (en) | Repetitive sequences derived from certain nitrogen fixing bacterial species |